Wonderful write-up about Amaroq by Callaghan Innovation. We are fortunate to be part of their Technology Incubator Programme! callaghaninnovation.govt.nz/customer-stori…

Was a pleasure to introduce Dr. Sarah Diermeier this morning as our Keynote Speaker at the BMS Postgraduate Symposium!

Meet the team: part 2 Our R&D team also includes three amazingly talented PhD students. Together we are exploring long non-coding RNAs as new therapeutic targets in cancer. Front row l->r: Dr. Megan O'Malley, Kaitlyn Tippett and Dr. Kathleen Lucere

New Zealand's Universities: Increase the PhD stipend to minimum wage - Sign the Petition! chng.it/Xjw5NZJQ via Change.org

R&D team photo with our Operations Manager Dr Nadine Brew (right), who visited us this week from Melbourne. Had two productive days of strategic planning to map out the next 12 month’s of our RNA therapeutics development program. Exciting times ahead!

Congrats to Meg, Meg and Kat who timed their combined PhD submissions to perfection! @megan17_taylor Dr. Megan O'Malley Dr. Sarah Diermeier Otago Biochemistry Dr. Kathleen Lucere

Really enjoyed watching the recording of this panel from experts in the field and especially hearing from my inspirational friend Laura McCambridge!!

So excited to have joined the team and be working on this amazing technology!

Grateful to have had the opportunity to attend and present my research at #cshlcancer22 this past week. Met some amazing people, heard about fantastic science and ofc the highlight was the famous CSHL lobster!! 🦞

When you aren’t equipped for this level of snow so have to improvise

So sad to be leaving this awesome group after 5 wonderful years but grateful for the experiences and excited for what’s to come!

For #WomensHistoryMonth, we're celebrating outstanding scientists in the biotech industry. We salute Sarah Diermeier, founder and chief scientific officer of Amaroq Therapeutics, which is focused on developing a new class of therapeutics that target long non-coding RNAs in cancer

Our latest review is out now on targeting #BreastCancer #Immunity #tme #trm #CancerResearch many thanks to Nature Reviews Cancer Peter Mac Cancer Centre Peter Mac Research TILs Working Group